Summary by Moomoo AI
On February 2, 2024, Bristol-Myers Squibb Company released its financial results for the fourth quarter of 2023 and the full year of 2023. The announcement highlighted a fourth-quarter revenue of $11.5 billion, with a GAAP EPS of $0.87 and a Non-GAAP EPS of $1.70. Full-year revenues reached $45.0 billion, with a GAAP EPS of $3.86 and a Non-GAAP EPS of $7.51. The company's in-line and new product portfolio revenues increased by 9% to $9.8 billion for the quarter and by 7% to $37.9 billion for the year. Bristol-Myers Squibb also reported on strategic acquisitions and collaborations aimed at strengthening its long-term growth profile, including the planned acquisitions of Karuna Therapeutics and RayzeBio, and a strategic collaboration with SystImmune. Additionally, the company completed the purchase of...Show More